Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613223 · ClinicalTrials.gov registry record · Phase 1
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
A Phase 1 study, sponsored by Annick Desjardins.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00613223 is a Phase 1 study that has completed, run by Annick Desjardins. The registered enrollment target is 49 participants.
The verdict
NCT00613223, a Phase 1 study, has completed, sponsored by Annick Desjardins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Primary Objective: To determine maximum tolerated dose \& dose limiting toxicity of vandetanib when combined with standard dosing of etoposide among patients with recurrent malignant glioma who are on \& not on enzyme-inducing anti-epileptic drugs (EIAEDs) Secondary Objectives: To assess safety \& tolerability of vandetanib + etoposide in this population; To evaluate pharmacokinetics of vandetanib among malignant glioma patients on \& not on EIAEDs when combined with etoposide. Exploratory Objective: To evaluate for evidence of anti-tumor activity of study regimen among recurrent malignant glioma patients including radiographic response rate, 6-month progression free survival (PFS) rate \& median PFS.
Interventions
- DRUG Vandetanib and Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613223
The ClinicalTrials.gov registry entry for NCT00613223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annick Desjardins, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vandetanib and Etoposide is the first listed.
NCT00613223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00613223 about?
NCT00613223 is a clinical study titled "Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas". Primary Objective: To determine maximum tolerated dose \& dose limiting toxicity of vandetanib when combined with standard dosing of etoposide among patients with recurrent malignant glioma who are on \& not on enzyme-inducing anti-epileptic drugs (EIAEDs) Secondary Objectives: To assess safety \& t...
What is the current status of trial NCT00613223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2008-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00613223?
The interventions under investigation include: Vandetanib and Etoposide (DRUG).
Who is sponsoring clinical trial NCT00613223?
This trial is sponsored by Annick Desjardins, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.